Article Authors: Xiaosu Ma, Charles T Benson, Randy Prescilla, Shuyu Zhang, Helle Linnebjerg, Elizabeth S LaBell, Linda A Morrow, Jeffrey A Jackson, Alex Nguyen, Liza L Ilag, Jennal L Johnson, Derek Leishman
Abstract
Human regular U-500 insulin (U-500R) is approved for subcutaneous (SC) injection in patients with diabetes requiring >200 units/day of insulin. Here, pharmacokinetic and pharmacodynamic (PK/PD) profiles following U-500R administered by continuous subcutaneous insulin infusion (CSII) and SC injection in adults with type 2 diabetes (T2D) on high-dose insulin were studied.
